HOME ·

CARSGEN-B

CARSGEN-B (02171.HK): CT1190B and CT071 Abstracts Published at ASH 2026
Tags：
CARSGEN-B02171.HKClinical Data
2026-11-05
CARSGEN-B (02171.HK): Phase Ib Results of CT041 Consolidation Therapy in Gastric Cancer Presented at ESMO
Tags：
NewTimeSpaceCARSGEN-B02171.HK
2026-10-26
CARSGEN-B (02171.HK): First Patient Dose of CT0596 in China Phase I
Tags：
CARSGEN-B02171.HKClinical Trial
2026-10-13
CARSGEN-B(02171.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 66.66 million, loss narrowed by 11.52% YoY
Tags：
CARSGEN-B02171.HKloss narrowed
2026-08-19
CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma
Tags：
CARSGEN-B02171.HKR&D Progress
2026-08-07
CARsgen Therapeutics (02171.HK) CT041 Postoperative Adjuvant Therapy Study Results Accepted for ESMO 2026 Poster Presentation
Tags：
CARSGEN-B02171.HKbiopharmaceutical
2026-07-15
CARSGEN-B(02171.HK): Kailimei® Secures NMPA Marketing Approval, the World’s First CAR-T Cell Therapy for Solid Tumors
Tags：
CARSGEN-B02171.HKNew Drug Application
2026-06-22
CARSGEN-B (02171.HK) plans to issue up to 23.7 million shares by placement, with estimated net proceeds of HKD 461.96 million
Tags：
CARSGEN-B02171.HKIssue shares
2026-05-15
CARSGEN-B(02171.HK) closed 8.18% higher, The full-day turnover stood at HKD 190.55 million
Tags：
CARSGEN-B02171.HKNewTimeSpace
2026-05-07